PACIRA BIOSCIENCES, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PACIRA BIOSCIENCES, INC. treasury stock, value, acquired, cost method for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $50.45M.
- PACIRA BIOSCIENCES, INC. treasury stock, value, acquired, cost method for the quarter ending 2025-12-31 was $51.02M.
- PACIRA BIOSCIENCES, INC. treasury stock, value, acquired, cost method for the quarter ending 2025-09-30 was $50.03M.
- PACIRA BIOSCIENCES, INC. treasury stock, value, acquired, cost method for fiscal 2025 was $151.44M, a 502.86% increase from fiscal 2024.
- PACIRA BIOSCIENCES, INC. treasury stock, value, acquired, cost method for fiscal 2024 was $25.12M.
- PACIRA BIOSCIENCES, INC. treasury stock, value, acquired, cost method for fiscal 2010 was $2.00K.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $151.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $50.45M 10-Q · filed 2026-04-30 | $201.89M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $51.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $151.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | $50.03M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $50.39M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.12M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $25.12M 10-Q · filed 2025-08-05 | |
| 2010-12-31 | $2.00K 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |